Disitertide

• UNSPSC Description:

  Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].

• Target Antigen:

  Apoptosis; PI3K; TGF-beta/Smad

• Type:

  Peptides

• Related Pathways:

  Apoptosis;PI3K/Akt/mTOR;Stem Cell/Wnt;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Disitertide.html

• Purity:

  98.12

• Solubility:

  H2O

• Smiles:

  C[C@@H](O)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H](C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CCSC)C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC(N)=O)=O)=O)=O)=O)=O)CC1=CNC2=CC=CC=C12)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Weight:

  1580.82

• References & Citations:

  [1]Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.|[2]Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220.|[3]Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654.|[4]Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489.|[5]Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75.Acta Histochem. 2023 Feb;125(2):152010.|Cancer Manag Res. 2018 Oct 10;10:4459-4470.|Cell Death Differ. 2021 Jan;28(1):219-232.|Cells. 2019 Jun 25;8(6):635.|Dig Dis Sci. 2020 Jul 15. |Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):9-16. |Front Immunol. 2017 Feb 3;8:91. |Int J Mol Med. 2019 May;43(5):2212-2220. |J BUON. 2021; 26(2): 435-443.|J Exp Clin Cancer Res. 2021 Feb 9;40(1):62.|Oncogene. 2019 Jun;38(23):4637-4654.|Funct Integr Genomics. 2024 Jul 12;24(4):123.|Int Immunopharmacol. 2024 Aug 21:141:112778.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Clinical Information:

  Phase 2

• CAS Number:

  272105-42-7